Abstracts Archive - Page 67 of 2607 - ACR Meeting Abstracts

Abstract Number: 0921 • ACR Convergence 2025
Fibrinogen Co-Modified with Malondialdehyde-Acetaldehyde and Citrulline Promotes Pro-Inflammatory Macrophage Differentiation Through p38 and NF-κB Signaling
Hannah Johnson¹, Wenxian Zhou², Michael Duryee¹, Carlos Hunter¹, Geoffrey Thiele¹ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Bellevue, NE
Background/Purpose: Citrulline (CIT) and malondialdehyde-acetaldehyde (MAA) co-adduct native proteins in RA tissues to create a dual pro-inflammatory and pro-fibrotic milieu. Our previous work demonstrated that…
Abstract Number: 0962 • ACR Convergence 2025
Spatial Proteomics Analysis of the organization of tertiary lymphoid structures in Systemic Sclerosis Skin
Dennis Bleck¹, Karen Drechsel², Tim Filla³, Yi-Nan Li⁴, Andrea-Hermina Györfi⁵, Alexandru-Emil Matei⁶ and Jörg Distler⁷, ¹University Hospital Düsseldorf, Department of Rheumatology, Hiller Research Center, Düsseldorf, Nordrhein-Westfalen, Germany, ²University Hospital Düsseldorf, Department of Rheumatology, Hiller Research center, Düsseldorf, Nordrhein-Westfalen, Germany, ³Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Germany, ⁴University Hospital of Düsseldorf, Düsseldorf, Nordrhein-Westfalen, Germany, ⁵Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany, ⁶Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany, Düsseldorf, Germany, ⁷University Hospital Duesseldorf and HHU, Duesseldorf, Germany
Background/Purpose: Systemic Sclerosis (SSc) is a rare autoimmune connective tissue disease and presents a significant medical challenge. It is characterized by fibrotic tissue remodeling, along…
Abstract Number: 0930 • ACR Convergence 2025
Potent and Selective Oral IRF5 Degrader, KT-579, Blocks Pro-Inflammatory Cytokines and Reduces Joint Swelling in a Mouse Model of Rheumatoid Arthritis
Ryan Camire¹, Yi Zhang², Virginia Massa², Jordan Leedberg², Erik Corcoran², Emily Lurier², Chris Carroll², Chris Ho², Dapeng Chen², Bradley Enerson², Revonda Mehovic², Ziyan Zhao², Lincoln Howarth², Susanne Breitkopf², Sarah Martinez², Melissa Ford², Xue Fei², Murugappan Sathappa², Juliet Williams³, Matthew Weiss³, Arsalan Shabbir³, Nello Mainolfi⁴ and Veronica Campbell², ¹Kymera Therapeutics, Watertown, MA ⁰²⁴⁷², MA, ²Kymera Therapeutics, Watertown, MA ⁰²⁴⁷², ³Kymera Therapeutics, Watertown, ⁴Kymera Therapeutics, Watertown, MA
Background/Purpose: IRF5, an undrugged transcription factor, is an autoimmune susceptibility gene that has been linked to RA and other autoimmune diseases including SLE, Sjögren’s, and…
Abstract Number: 0506 • ACR Convergence 2025
Discovery-based Identification of Non-canonical Autoantibody Specificities in Ro Seronegative Sjögren’s Disease Using High-content Human Proteome Arrays
Songyuan Yao¹, Christina Lawrence¹, Hope Christakos², Charmaine Lopez-Davis¹, Bhuwan Khatri¹, Tommi C. Taylor¹, Astrid Rasmussen¹, Kiely Grundahl², R Hal Scofield¹, Blake M. Warner³, Judith James¹, Joel Guthridge¹, Christopher J. Lessard¹ and A. Darise Farris¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, ³National Institutes of Health, Bethesda, MD
Background/Purpose: Clinical tests for Sjögren’s disease (SjD) often overlook Ro-seronegative (RoNeg) cases, leading to delayed or missed diagnoses. Identifying additional serum autoantibodies could improve diagnostic…
Abstract Number: 0605 • ACR Convergence 2025
The Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) Predicts Worsening Self-Efficacy in the Patients from the Almenara Lupus Cohort
Anubhav Singh¹, Rocío Gamboa-Cárdenas², Victor Pimentel-Quiroz³, Zoila Rodriguez-Bellido⁴, Cesar Pastor-Asurza⁵, Risto Perich-Campos⁶, Manuel Ugarte-Gil⁷ and Graciela Alarcón⁸, ¹Baptist hospital of southeast Texas, Beaumont, TX, ²Universidad Científica del Sur, Lima, Peru, ³Universidad Científica del Sur, San Isidro, Peru, ⁴Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁵Hospital Nacional Guillermo Almenara Irigoyen, Lima, Pakistan, ⁶Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, La Molina, Peru, ⁷Universidad Cientifica del Sur, Lima, Peru, ⁸The University of Alabama at Birmingham, Oakland, CA
Background/Purpose: The Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) was developed to ascertain frailty in systemic lupus erythematosus (SLE) patients. The aim of this…
Abstract Number: 0641 • ACR Convergence 2025
Safety and efficacy of autologous CD19-CAR T-cell therapy in patients with autoimmune disease – data from the CASTLE Phase I/II basket study
Melanie Hagen¹, Andreas Wirsching¹, Fabian Müller², Soraya Kharboutli³, Christina Bergmann¹, Sebastian Böltz¹, Jule Taubmann⁴, Carlo Tur¹, Laura Bucci¹, Simon Völkl³, Michael Aigner³, Sascha Kretschmann³, Louis Schuster⁴, Koray Tascilar⁴, Silvia Spoerl³, Ingrid Vasova³, Panagiotis Garantziotis¹, Daniel Aletaha⁵, Hans-Peter Kiener⁶, gerlando Natalello⁷, Franco Locatelli⁸, Maria Antonietta D'Agostino⁹, Aline Bozec¹, Linda Hanssens¹⁰, Dirk De Vries¹⁰, Ricardo Grieshaber-Bouyer¹¹, Andreas Mackensen¹² and Georg Schett¹³, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ²University Hospital of Erlangen, Erlangen, Germany, ³Department of Medicine ⁵ - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁴Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁵Medical University Vienna, Wien, Austria, ⁶Medical University of Vienna, Vienna, Austria, Vienna, Austria, ⁷Division of Rheumatology and Clinical Immunology - Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁸IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, ⁹Catholic University of the Sacred Heart, Rome, Rome, Italy, ¹⁰Miltenyi Biomedicine, Bergisch Gladbach, Bergisch Gladbach, Germany, ¹¹University Hospital Erlangen, Erlangen, Germany, ¹²Department of Medicine ⁵ - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Germany, ¹³Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany
Background/Purpose: Engineered T cells expressing a chimeric antigen receptor (CAR) binding CD19 are powerful tools to deplete B-cells, representing an attractive therapy for severe autoimmune…
Abstract Number: 0980 • ACR Convergence 2025
Expansion of Viral-Reactive CD8+ T cell Repertoire Stratified by Pathotype in New-onset ACPA+ Rheumatoid Arthritis
Carl Coyle¹, Wittaya Suwakulsiri², Lukas Andriessen³, Megan Soon⁴, Pascale Wehr⁵, Sumera Qureshi⁶, Christopher Altmann⁷, Annabelle Small⁸, Vincent Wong⁹, Andrew Cope⁶, Kevin Wei¹⁰, Hendrik Nel⁵, Mihir Wechalekar¹¹ and Ranjeny Thomas², ¹Kings College London, London, United Kingdom, ²Frazer Institute, University of Queensland, Brisbane, Queensland, Australia, ³Frazer Institute, University of Queensland, Woolloongabba, Queensland, Australia, ⁴Frazer Institute, The University of Queensland, Brisbane, Australia, ⁵University of Queensland, Woolloongabba, Queensland, Australia, ⁶King's College London, London, United Kingdom, ⁷Flinders University, Adelaide, Australia, ⁸Flinders University, Bedford Park, South Australia, Australia, ⁹College of Medicine and Public Health, Bedford Park, South Australia, Australia, ¹⁰Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ¹¹Flinders Medical Centre, Adelaide, Australia
Background/Purpose: Development of Rheumatoid Arthritis (RA) is strongly associated with specific HLA-DRB1 genotypes and the HLA-DR antigen binding groove, the shared epitope. HLA-B*08 also increases…
Abstract Number: 0515 • ACR Convergence 2025
Inverse Correlation Between Type I Interferon Pathway Activation And Unstimulated Whole Salivary Flow In Sicca Patients
Nikolaos Marketos¹, Charalampos Skarlis¹, Sylvia Raftopoulou¹, Ada Gjyrezi², Paul Zumbo³, Doron Betel³, Ioanna E. Stergiou⁴, Michael Voulgarelis⁴, Paraskevi Giannakakou⁵ and Clio Mavragani⁶, ¹Molecular Physiology and Clinical Applications Unit, Department of Physiology, Medical School of Athens, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ²Department of Medicine, Weill Cornell Medicine, New York, NY, USA, and Department of Physiology , National & Kapodistrian University of Athens, Athens, Greece, New York, ³Department of Physiology & Biophysics, Applied Bioinformatics Core, Weill Cornell Medicine, New York, NY, USA, New York, ⁴Outpatient Rheumatology Clinic, Department of Pathophysiology, Medical School of Athens, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ⁵Department of Medicine, Weill Cornell Medicine, New York, NY, USA, and Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA, New York, ⁶National and Kapodistrian University of Athens, Athens, Greece
Background/Purpose: Oral and ocular dryness are hallmarks in patients with Sjögren’s disease (SjD). Given that activation of interferon (IFN) pathways has been shown to be…
Abstract Number: 0036 • ACR Convergence 2025
Integrated Analysis of Polygenic and Environmental Risk Scores for Late-Onset Systemic Lupus Erythematosus
Mehmet Hocaoglu¹ and Amr Sawalha², ¹University of Pittsburgh Medical Center, Piitsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Polygenic risk scores (PRS) have been constructed to summarize genetic risk but there is limited research on environment-wide analysis of risk factors for systemic…
Abstract Number: 0945 • ACR Convergence 2025
Nerve Injury-Induced Protein-1 (Ninj1) Deficiency Aggravates Murine Lupus Through Modulation of Macrophage Polarization
Jorge Romo-Tena¹, Luz Blanco², Shuichiro Nakabo³, Victoria Hoffman⁴, Norio Hanata⁵, Mingzeng Zhang², Carmelo Carmona-Rivera⁵, Eduardo Patino-Martinez⁶, Dillon Claybaugh², Zu-Xi Yu² and Mariana Kaplan⁵, ¹Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²NIH, Bethesda, MD, ³NIAMS, NIH, Bethesda, MD, ⁴Diagnostic and Research Services Branch, Division of Veterinary Resources, Office of Research Services, National Institutes of Health, Bethesda, MD, Bethesda, ⁵Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, Bethesda, MD, ⁶NIH/NIAMS, Bethesda, MD
Background/Purpose: Nerve injury-induced protein-1 (Ninj1) is an adhesion molecule that plays various roles in immune and stromal cells, including the modulation of inflammation and a…
Abstract Number: 0642 • ACR Convergence 2025
Belimumab-Based Triple Therapy in Proliferative Lupus Nephritis: Renal Outcomes and Glucocorticoid Tapering in a Real-World Multicenter Cohort
Paola Vidal Montal¹, Javier Narváez², Aina Fabregat³, Iñigo Rúa-Figueroa⁴, José María Pego-Reigosa⁵, Andrea Hernández-martín⁶, Clara Moriano⁷, Maria Garcia-Villanueva⁸, Sandra Garrote Corral⁹, Sergi Heredia¹⁰, Julia Martínez Barrio¹¹, Júlia Bernardez Moreno¹², Paloma Vela Casasempere¹³, Beatriz Tejera Segura¹⁴, Leyre Riancho¹⁵, Francisco Javier Novoa¹⁶, Vicenç Torrente-Segarra¹⁷, Maria Piqueras García¹⁸, Beatriz Frade Sosa¹⁹, José Gomez-Puerta²⁰, Consuelo Ramos Giraldez²¹, Tarek Salman Montes²², María Galindo-Izquierdo²³, EVA GLORIA TOMERO MURIEL²⁴, Jaime calvo²⁵, Jorge Juan Fragío Gil²⁶, Marta De la Rubia Navarro²⁷, Berta Magallares²⁸ and Irene Altabás-González²⁹, ¹Bellvitge University Hospital, Barcelona, Spain, ²Hospital Universitario de Bellvitge, Barcelona, Spain, ³Department of Rheumatology. Hospital Universitario de Bellvitge., Barcelona, Spain, ⁴Hospital de Gran Canaria Doctor Negrin, Las Palmas GC, Spain, ⁵Department of Rheumatology, University Hospital of Vigo, Vigo, Spain; IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Galicia Sur Health Research Institute, Vigo, Spain, ⁶Hospital Universitario de Gran Canaria Dr Negrín, Las palmas, Spain, ⁷Hospital León, LEON, Castilla y Leon, Spain, ⁸Hospital Ramón y Cajal, Madrid, Spain, ⁹Hospital Ramón y Cajal, Madrid, ¹⁰Hospital Moisès Broggi, Barcelona, Spain, ¹¹Department of Rheumatology, Hospital Gregorio Marañón, Madrid, Spain, Madrid, Madrid, Spain, ¹²Hospital de Sant Pau, Barcelona, Spain, ¹³Hospital General Universitario Alicante, Alicante, Comunidad Valenciana, Spain, ¹⁴Hospital Insular de Gran Canaria, Las palmas, Spain, ¹⁵Hospital de Sierrallana, Torrelavega, ¹⁶Hospital Insular de Gran Canaria, Las palmas, ¹⁷Hospital Comarcal Alt Penedés Garraf, Vilafranca del Penedès, Spain, ¹⁸Servicio Murciano de Salud, Murcia, Spain, ¹⁹Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, ²⁰Rheumatology Department, Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ²¹Hospital Universitario Virgen de Valme, Servicio de Reumatología, Seville, Spain, ²²Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ²³Department of Rheumatology, Hospital Universitario ¹² de Octubre, Madrid, Spain, Madrid, Madrid, Spain, ²⁴Hospital Universitario de la Princesa, Madrid, Spain, ²⁵Hospital de Araba, Vitoria, Spain, ²⁶Hospital General Universitario, Valencia, Spain, ²⁷Hospital de La Fe, Valencia, ²⁸Hospital de Sant Pau, Bareclona, ²⁹Complejo Hospitalario de Vigo, Vigo, Spain
Background/Purpose: The newly published ACR guidelines recommend initiating triple therapy for all patients with proliferative lupus nephritis (LN). While belimumab (BEL) has demonstrated efficacy in…
Abstract Number: 0032 • ACR Convergence 2025
Protein Language Model-Guided Homology Identifies Microbial Enzymes Linked to Fibrosis-Prone IgG4-RD and Crohn’s Disease
Kumar Thurimella¹, Ahmed Mohamed², Chenhao Li³, Tommi Vatanen⁴, Daniel Graham³, Roisin Owens⁵, Sabina Leanti La Rosa⁶, Damian Plichta³, Sergio Bacallado⁵ and Ramnik Xavier⁷, ¹University of Colorado School of Medicine, Aurora, CO, ²Broad Institute, Boston, ³Broad Institute, Cambridge, MA, ⁴University of Helsinki, Helsinki, Finland, ⁵University of Cambridge, Cambridge, United Kingdom, ⁶NMBU, As, Norway, ⁷Harvard Medical School, Boston, MA
Background/Purpose: Uncharacterized microbial enzymes in metagenomics are difficult to annotate, especially in fibrosis-prone conditions like IgG4-related disease (IgG4-RD) and Crohn’s disease (CD), where microbial carbohydrate…
Abstract Number: 0524 • ACR Convergence 2025
Radiographic progression in sacroiliac joints in five years follow up in non-radiographic axial spondyloarthritis patients and the predictive factors
Esra Erpek¹, Hasan Kocaayan², Elif Ediboğlu³, Ayberk Sinci⁴, Özgür Tosun⁴, Dilek Solmaz³ and Servet Akar⁵, ¹İzmir Katip Çelebi Üniversitesi, Romatoloji Bilim Dalı, İzmir, Izmir, Turkey, ²Izmir Katip Çelebi University School of Medicine, Rheumatology, Turkey, İzmir, Turkey, ³Izmir Katip Çelebi University School of Medicine, Rheumatology, Turkey, İzmir, Izmir, Turkey, ⁴İzmir Katip Çelebi Üniversitesi, Radyoloji Bilim Dalı, İzmir, Izmir, Turkey, ⁵Department of Medicine, Izmir Katip Çelebi University School of Medicine, Izmir, Turkey
Background/Purpose: This study aimed to assess the rate of progression in sacroiliac joints in non-radiographic axial spondyloarthritis (nr-axSpA) and to identify the predictive factors for…
Abstract Number: 0518 • ACR Convergence 2025
Deregulation of PSGL-1, HLA-DR and IFNα expression in peripheral innate immune cells of primary Sjögren Syndrome patients
Santos Castañeda¹, Alejandra Ramos-Manzano², Ines Sanchez-Abad³, Miren Uriarte-Ecenarro⁴, M. Paula Alvarez-Hernandez⁴, Esther San-Antonio⁴, Esther Vicente-Rabaneda⁵ and Ana Urzainqui⁴, ¹Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ²Hospital Unversitario de la Princesa, Madrid, Madrid, Spain, ³Hospitla de la Princesa, Madrid, Spain, ⁴Hospital de la Princesa, Madrid, Madrid, Spain, ⁵Hospital Universitario de La Princesa, Madrid, Spain
Background/Purpose: Primary Sjögren's Syndrome (pSS) is an autoimmune disease characterized by lymphocytic infiltration of exocrine glands and systemic manifestations including cutaneous and renal involvement. Phagocytes--monocytes,…
Abstract Number: 0993 • ACR Convergence 2025
NOD2 mutations mediate IL-17 predisposition in patients with Blau syndrome
Leah Huey¹, Emily Vance², Bryce Binstadt³ and Ruth Napier², ¹Oregon Health & Science University, Denver, CO, ²University of Colorado Anschutz, Aurora, CO, ³University of Minnesota, Minneapolis, MN
Background/Purpose: Blau syndrome is a pediatric rheumatic disease characterized by dermatitis, arthritis, and uveitis. Blau syndrome is caused by inborn or de novo mutations in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].